GLOBAL LIVER INSTITUTE
The situation in Congress remains unclear as the House budget resolution calls for possible significant Medicaid cuts, while the Senate attempts to steer clear of policies reducing Medicaid and/or Medicare benefits.
As of January 2025, major changes to Medicare Part D under the Inflation Reduction Act are now in effect, making prescription drugs more affordable for millions of patients.
February is Rare Liver Diseases Month! This year, our campaign is shining a spotlight on Rare and Rural.
Liver cancer continues to be a growing public health concern, with new research and treatment innovations shaping the future of care. This newsletter brings you the latest advancements in the field, including promising therapies, diagnostic breakthroughs, and discussions on the rising impact of metabolic and alcohol-related liver diseases. Stay informed with expert insights and emerging strategies that could improve patient outcomes.
Hepatitis C infection is a chronic infection of the liver by the hepatitis C virus (HCV) that continues to affect millions of people across the globe. Left untreated, infection with hepatitis C leads to worsening liver damage and puts the body in distress, which can lead to brain fog, abdominal pain, and internal bleeding.
The new U.S. Congress is at work in Washington, DC. It is unclear if the healthcare legislation that came so close to passage last December will be included in a March appropriations package.
February is Rare Liver Diseases Month! This year, our campaign is shining a spotlight on Rare and Rural.
In recent years, liver cancer has emerged as a significant global health concern, with increasing incidence rates and a pressing need for innovative treatment strategies.
As of January 2025, major changes to Medicare Part D under the Inflation Reduction Act are now in effect, making prescription drugs more affordable for millions of patients.
As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a spotlight on the critical need for awareness and education about rare liver diseases during Rare Liver Diseases Month.
GLI was very pleased to see the U.S. Centers for Medicare and Medicaid Services (CMS) take the step towards expanding coverage for anti-obesity medications when used to treat obesity in the Medicare Part D and Medicaid programs.
GLI celebrates the release of bill text last night for a continuing resolution (CR) for FY2025 from the U.S. House of Representatives that includes Medicare coverage of multi-cancer early detection screening tests and defines standards and payments for these diagnostic tests.
